Antibodies comprising chimeric constant domains

Patent metadata

Field	Value
Publication number	US-9359437-B2
Application number	US-201414170166-A
Country	US
Kind code	B2
Filing date	Jan 31, 2014
Priority date	Feb 1, 2013
Publication date	Jun 7, 2016
Grant date	Jun 7, 2016

Abstract

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

First claim

What is claimed:

1. A recombinant polypeptide comprising a heavy chain constant (CH) region comprising, from N-terminus to C-terminus, a CH1 domain, a chimeric hinge, a CH2 domain, and a CH3 domain wherein:
(a) the CH1 domain comprises the amino acid sequence DKKV or DKRV from positions 212 to 215 (EU numbering),
(b) the chimeric hinge comprises a human IgG1 or a human IgG4 upper hinge amino acid sequence from positions 216 to 227 (EU numbering) and a human IgG2 lower hinge amino acid sequence PCPAPPVA (SEQ ID NO: 3) from positions 228 to 236 (EU numbering),
(c) the CH2 domain comprises a human IgG4 CH2 domain amino acid sequence from positions 237 to 340 (EU numbering) comprising the amino acid sequence of SEQ ID NO: 10, and
(d) the CH3 domain comprises a human IgG1 or a human IgG4 CH3 domain sequence from positions 341 to 447 (EU numbering).

2. The recombinant polypeptide of claim 1 , wherein the CH region has an amino acid sequence at least 99% identical to any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 37, or SEQ ID NO: 38.

3. The recombinant polypeptide of claim 1 , wherein the CH1 domain comprises the amino acid sequence DKKV (SEQ ID NO: 4), and the chimeric hinge comprises the amino acid sequence EPKSCDKTHTCPPCPAPPVA (SEQ ID NO: 8).

4. The recombinant polypeptide of claim 1 , wherein the CH1 domain comprises the amino acid sequence DKRV (SEQ ID NO: 5), and the chimeric hinge comprises the amino acid sequence ESKYGPPCPPCPAPPVA (SEQ ID NO: 9).

5. The recombinant polypeptide of claim 1 , wherein the CH3 domain comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 11, or SEQ ID NO: 12, SEQ ID NO: 41, and SEQ ID NO: 42.

6. The recombinant polypeptide of claim 1 , wherein the recombinant polypeptide is an antigen-binding protein.

7. The recombinant polypeptide of claim 1 , wherein the recombinant polypeptide is a receptor-Fc fusion protein.

8. The recombinant polypeptide of claim 1 , wherein the recombinant polypeptide is an antibody.

9. The recombinant polypeptide of claim 8 , wherein the antibody exhibits direct cytotoxic activity of less than 20% cytolysis, or less than 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable cytolysis, at an antibody concentration of at least 10 nM.

10. The recombinant polypeptide of claim 9 , wherein the direct cytotoxic activity is at least about 5-fold less, or at least about 10-fold less than the direct cytotoxic activity of a corresponding antibody comprising a wild-type IgG1 or wild-type IgG4 CH region.

11. A recombinant polypeptide, wherein the polypeptide comprises N′-VD1-X1-Y1-Y2-X2-X3-C′, wherein:
(a) N′ is the N-terminus and C′ is the C-terminus of the polypeptide,
(b) VD1 is an amino acid sequence comprising an antigen-binding domain,
(c) X1 is an amino acid sequence comprising a domain selected from the group consisting of an IgG1 CH1 domain, an IgG4 CH1 domain, and at least positions 212-215 (EU numbering) of an IgG1 or IgG4 CH1 domain,
(d) Y1 comprises an amino acid sequence from positions 216-227 (EU numbering) of an IgG1 or IgG4 hinge region,
(e) Y2 comprises the human IgG2 lower hinge region amino acid sequence PCPAPPVA (SEQ ID NO: 3) from positions 228 to 236 (EU numbering),
(f) X2 is an amino acid sequence comprising an IgG4 CH2 domain comprising the amino acid sequence of SEQ ID NO. 10, and
(g) X3 is an amino acid sequence comprising an IgG1 CH3 domain or an IgG4CH3 domain.

12. The recombinant polypeptide of claim 11 , wherein the polypeptide comprises an amino acid sequence at least 99% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 37, or SEQ ID NO: 38.

13. The recombinant polypeptide of claim 11 , wherein X1 comprises the amino acid sequence DKKV (SEQ ID NO: 4), and Y1-Y2 comprises a chimeric hinge consisting of the amino acid sequence EPKSCDKTHTCPPCPAPPVA (SEQ ID NO: 8).

14. The recombinant polypeptide of claim 11 , wherein X1 comprises the amino acid sequence DKRV (SEQ ID NO: 5), and Y1-Y2 comprises a chimeric hinge consisting of the amino acid sequence ESKYGPPCPPCPAPPVA (SEQ ID NO: 9).

15. The recombinant polypeptide of claim 11 , wherein X3 comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 41, and SEQ ID NO: 42.

16. The recombinant polypeptide of claim 11 , wherein the recombinant polypeptide is an isolated antigen-binding protein.

17. The recombinant polypeptide of claim 11 , wherein the recombinant polypeptide is a receptor-Fc fusion protein.

18. The recombinant polypeptide of claim 11 , wherein the recombinant polypeptide is an isolated antibody.

19. The recombinant polypeptide of claim 18 , wherein the antibody exhibits direct cytotoxic activity of less than 20% cytolysis, or less than 10%, or 5%, 4%, 3%, 2%, or even 0% or undetectable cytolysis, at an antibody concentration of at least 10 nM.

20. The recombinant polypeptide of claim 19 , wherein the direct cytotoxic activity is at least about 5-fold less, or at least about 10-fold less than the direct cytotoxic activity of a corresponding antibody comprising a wild-type IgG1 or wild-type IgG4 CH region.

21. A composition comprising a recombinant polypeptide of claim 1 or claim 11 .

Assignees

• Regeneron Pharma

Inventors

• Davis Samuel
• Smith Eric
• Patel Supriya

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K16/2809 Primary

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• C07K2317/31

  multispecific · CPC title